These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 8180328

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S, Barbano B, Cianci R, Gigante A, Di Donato D, Asllanaj B, Dimko M, Mariotti A, Morabito S, Pugliese F.
    G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
    [Abstract] [Full Text] [Related]

  • 3. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
    Barata JD, Oliveira C, Bruges M, Gusmão L, Santana A, Ponce P, Simões J, Freire I, Crespo F, da Silva AN.
    Acta Med Port; 1992 Feb; 5(2):65-70. PubMed ID: 1317657
    [Abstract] [Full Text] [Related]

  • 4. [Therapeutic indications of low molecular weight heparins].
    Samama MM, Michaut-Paterno F.
    Arch Mal Coeur Vaiss; 1991 Nov; 84(11 Suppl):1733-43. PubMed ID: 1662941
    [Abstract] [Full Text] [Related]

  • 5. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M, Weltermann A, Nieszpaur-Los M, Schneider B, Fassolt A, Lechner K, Eichler HG, Kyrle PA.
    Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
    [Abstract] [Full Text] [Related]

  • 6. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.
    Lavaud S, Canivet E, Wuillai A, Maheut H, Randoux C, Bonnet JM, Renaux JL, Chanard J.
    Nephrol Dial Transplant; 2003 Oct; 18(10):2097-104. PubMed ID: 13679486
    [Abstract] [Full Text] [Related]

  • 7. Neutralization of enoxaparine-induced bleeding by protamine sulfate.
    Van Ryn-McKenna J, Cai L, Ofosu FA, Hirsh J, Buchanan MR.
    Thromb Haemost; 1990 Apr 12; 63(2):271-4. PubMed ID: 2163553
    [Abstract] [Full Text] [Related]

  • 8. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J, Raschke R.
    Chest; 2004 Sep 12; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Low molecular weight heparin: a critical analysis of clinical trials.
    Green D, Hirsh J, Heit J, Prins M, Davidson B, Lensing AW.
    Pharmacol Rev; 1994 Mar 12; 46(1):89-109. PubMed ID: 8190751
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative.
    Kuziej J, Litinas E, Hoppensteadt DA, Liu D, Walenga JM, Fareed J, Jeske W.
    Clin Appl Thromb Hemost; 2010 Aug 12; 16(4):377-86. PubMed ID: 20460347
    [Abstract] [Full Text] [Related]

  • 14. Haemodialysis with low MW heparin: dosage requirements for the elimination of extracorporeal fibrin formation.
    Lane DA, Ireland H, Flynn A, Anastassiades E, Curtis JR.
    Nephrol Dial Transplant; 1986 Aug 12; 1(3):179-87. PubMed ID: 2955253
    [Abstract] [Full Text] [Related]

  • 15. Mechanism of low-molecular-weight heparin reversal by platelet factor 4.
    Fiore MM, Mackie IM.
    Thromb Res; 2009 May 12; 124(1):149-55. PubMed ID: 19195682
    [Abstract] [Full Text] [Related]

  • 16. [Pharmacologic and clinical principles for rational anti-thrombotic preventive treatment with low molecular weight heparin].
    Pindur G, Köhler M, Heiden M, Leipnitz C, Rupp KH, Wenzel E.
    Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir; 1990 May 12; ():1149-55. PubMed ID: 1983502
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological profile of reviparin-sodium.
    Hoppensteadt D, Jeske W, Fareed J.
    Blood Coagul Fibrinolysis; 1993 Dec 12; 4 Suppl 1():S11-6. PubMed ID: 8180323
    [Abstract] [Full Text] [Related]

  • 18. [Minimal heparinization in dialysis patients with increased risk of bleeding].
    Klingel R, Wandel E, Hafner G, Meyer zum Büschenfelde KH, Köhler H.
    Dtsch Med Wochenschr; 1993 Dec 23; 118(51-52):1878-83. PubMed ID: 8287777
    [Abstract] [Full Text] [Related]

  • 19. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects.
    Harenberg J, Stehle G, Dempfle CE, von Hodenberg E, Heene DL.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989 Dec 23; 116(6):967-80. PubMed ID: 2483715
    [Abstract] [Full Text] [Related]

  • 20. Low molecular weight heparin in haemodialysis for chronic renal failure: dose finding study of CY222.
    Ireland H, Lane DA, Flynn A, Pegrum AC, Curtis JR.
    Thromb Haemost; 1988 Apr 08; 59(2):240-7. PubMed ID: 2838924
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.